天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

阿哌沙班,Apixaban
  • 阿哌沙班,Apixaban
  • 阿哌沙班,Apixaban
  • 阿哌沙班,Apixaban

阿哌沙班,阿哌沙班原料藥,阿哌沙班工廠

價(jià)格 詢價(jià)
包裝 1kg
最小起訂量 1kg
發(fā)貨地 山東
更新日期 2024-08-01

產(chǎn)品詳情

中文名稱:阿哌沙班英文名稱:Apixaban
CAS:503612-47-3產(chǎn)地: 山東
保存條件: Refrigerator純度規(guī)格: 99.21%
產(chǎn)品類別: 醫(yī)藥原料藥
級(jí)別: 醫(yī)藥級(jí)別名: apaxaban,apixaban api,apixaban cas, cas 503612-47-3
分子式: C25H25N5O4用途: Cerebro-cardiovascular
外觀性狀: White powder
2024-08-01 阿哌沙班 Apixaban 1kg/RMB 山東 Refrigerator 99.21% 醫(yī)藥原料藥

Product name: Apixaban

Cas NO.: 503612-47-3

M.F: C25H25N5O4

M.W.: 459.5

Capacity: 200KG/M

Usage: Cerebro-cardiovascular

General: Apixaban is a potent, orally active, reversible, direct, and highly selective factor Xa active site inhibitor with antithrombotic activity. Apixaban inhibits free and thrombus-bound factor Xa and inhibits prothrombin activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits thrombin-induced platelet aggregation. Through inhibition of factor Xa, apixaban inhibits thrombin generation and inhibits thrombus formation. The preclinical test results in animal models show that apixaban has antithrombotic effect at a dose level that does not affect the hemostatic function, and can prevent arterial and venous thrombosis. 

 

Product introduce: Apixaban is an anticoagulant used to prevent venous thromboembolism and atrial fibrillation stroke. It is a direct factor Xa inhibitor. Apixaban can be used for antithrombotic therapy in patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) of atrial fibrillation. Clinical trials have confirmed the safety and effectiveness of Apixaban in patients with atrial fibrillation at the recommended dose. A new oral anticoagulant including Apixaban combined with P2Y12 inhibitor is currently recommended by North American guidance for preventing stroke and systemic embolism in patients with ACS or PCI with atrial fibrillation.

FunctionApixaban can prevent thrombin generation and thrombosis, and play an anticoagulant role by inhibiting coagulation factor Xa.

 

Origin: Apixaban has been listed in Europe since May 2011. The drug was developed by a joint venture between Pfizer and Bristol-Myers Squibb.

 

Drug efficacy: Apixaban is the third new oral anticoagulant listed after dabigatran and rivaroxaban. It has been approved in Europe to prevent venous thromboembolic events in patients undergoing elective hip or knee replacement surgery. The experimental results of these three oral anticoagulants show that rivaroxaban and apixaban stand out in the RECORD test and the ADVANCE test respectively. Experts say that rivaroxaban seems to have a slightly better effect, but the bleeding situation is more serious than that of apixaban. Experts attribute these differences to the time of administration. In the RECORD trial, rivaroxaban was administered 6-8 hours after operation, while in the ADVANCE trial, apixaban was administered 18 hours after operation. The closer the administration time of these drugs is to the operation, the better the curative effect, but the higher the risk of bleeding.


關(guān)鍵字: apixaban api;apaxaban;apixaban factory;apixaban cas;cas 503612-47-3;

公司簡(jiǎn)介

濟(jì)南洣林藥業(yè)有限公司成立于2012年,是一家以創(chuàng)新為導(dǎo)向的現(xiàn)代制藥企業(yè)。洣林藥業(yè) 具有卓越的研發(fā)能力和完整的產(chǎn)業(yè)基地,具有國(guó)際質(zhì)量管理體系。致力于醫(yī)藥及高級(jí)醫(yī)藥中間體的研發(fā)、生產(chǎn)和定制。
成立日期 2012-04-12 (13年) 注冊(cè)資本 貳佰萬(wàn)元整
員工人數(shù) 10-50人 年?duì)I業(yè)額 ¥ 500萬(wàn)-1000萬(wàn)
主營(yíng)行業(yè) 醫(yī)藥中間體,合成材料中間體,原料藥,有機(jī)合成藥 經(jīng)營(yíng)模式 貿(mào)易,工廠
  • 濟(jì)南洣林醫(yī)藥技術(shù)有限公司
非會(huì)員
  • 公司成立:13年
  • 注冊(cè)資本:貳佰萬(wàn)元整
  • 企業(yè)類型:有限責(zé)任公司
  • 主營(yíng)產(chǎn)品:阿哌沙班,阿哌沙班中間體,魯拉西酮,塞卡替尼
  • 公司地址:山東省濟(jì)南市高新區(qū)天辰路2177號(hào)聯(lián)合財(cái)富廣場(chǎng)1號(hào)樓2208室
詢盤

阿哌沙班,阿哌沙班原料藥,阿哌沙班工廠相關(guān)廠家報(bào)價(jià)

更多
產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
¥500
VIP6年
湖北阡陌生物科技有限公司
2025-01-10
詢價(jià)
VIP3年
湖北威德利化學(xué)試劑有限公司
2025-01-10
詢價(jià)
VIP13年
深圳菲斯生物科技有限公司
2025-01-10
詢價(jià)
VIP6年
湖北摩科化學(xué)有限公司
2025-01-10
詢價(jià)
VIP6年
武漢弘德悅欣醫(yī)藥科技有限公司
2025-01-10
詢價(jià)
VIP6年
武漢裕清嘉衡藥業(yè)有限公司
2025-01-10
詢價(jià)
VIP6年
武漢弘德悅欣醫(yī)藥科技有限公司
2025-01-10
詢價(jià)
VIP1年
濟(jì)南洣林醫(yī)藥技術(shù)有限公司
2025-01-10
詢價(jià)
VIP4年
濟(jì)南安德醫(yī)藥科技有限公司
2025-01-10
詢價(jià)
VIP4年
武漢東康源科技有限公司
2025-01-10
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的